287 related articles for article (PubMed ID: 34364539)
1. Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.
Eid R; Yan CH; Stevens W; Doherty TA; Borish L
J Allergy Clin Immunol; 2021 Aug; 148(2):309-318. PubMed ID: 34364539
[TBL] [Abstract][Full Text] [Related]
2. Cellular interactions in aspirin-exacerbated respiratory disease.
Badrani JH; Doherty TA
Curr Opin Allergy Clin Immunol; 2021 Feb; 21(1):65-70. PubMed ID: 33306487
[TBL] [Abstract][Full Text] [Related]
3. Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.
Buchheit KM; Cahill KN; Katz HR; Murphy KC; Feng C; Lee-Sarwar K; Lai J; Bhattacharyya N; Israel E; Boyce JA; Laidlaw TM
J Allergy Clin Immunol; 2016 May; 137(5):1566-1576.e5. PubMed ID: 26691435
[TBL] [Abstract][Full Text] [Related]
4. Aspirin-exacerbated respiratory disease.
Wangberg H; White AA
Curr Opin Immunol; 2020 Oct; 66():9-13. PubMed ID: 32299015
[TBL] [Abstract][Full Text] [Related]
5. Update on Aspirin-Exacerbated Respiratory Disease.
Woessner KM
Curr Allergy Asthma Rep; 2017 Jan; 17(1):2. PubMed ID: 28097500
[TBL] [Abstract][Full Text] [Related]
6. Association of interleukin-25 levels with development of aspirin induced respiratory diseases.
Lee JU; Chang HS; Lee HJ; Bae DJ; Son JH; Park JS; Choi JS; Hwang HG; Park CS
Respir Med; 2017 Feb; 123():71-78. PubMed ID: 28137499
[TBL] [Abstract][Full Text] [Related]
7. Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease.
Luskin K; Thakrar H; White A
Immunol Allergy Clin North Am; 2020 May; 40(2):329-343. PubMed ID: 32278455
[TBL] [Abstract][Full Text] [Related]
8. Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
Liu T; Kanaoka Y; Barrett NA; Feng C; Garofalo D; Lai J; Buchheit K; Bhattacharya N; Laidlaw TM; Katz HR; Boyce JA
J Immunol; 2015 Oct; 195(8):3537-45. PubMed ID: 26342029
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells.
Rusznak M; Peebles RS
Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):38-45. PubMed ID: 30516547
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.
Buchheit KM; Lewis E; Gakpo D; Hacker J; Sohail A; Taliaferro F; Berreondo Giron E; Asare C; Vukovic M; Bensko JC; Dwyer DF; Shalek AK; Ordovas-Montanes J; Laidlaw TM
J Allergy Clin Immunol; 2021 Aug; 148(2):574-584. PubMed ID: 34144111
[TBL] [Abstract][Full Text] [Related]
11. The time course of nasal cytokine secretion in patients with aspirin-exacerbated respiratory disease (AERD) undergoing aspirin desensitization: preliminary data.
San Nicoló M; Högerle C; Gellrich D; Eder K; Pfrogner E; Gröger M
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):445-452. PubMed ID: 31655881
[TBL] [Abstract][Full Text] [Related]
12. [Advances in aspirin-exacerbated respiratory disease (AERD)].
Higashi N; Mitsui C; Taniguchi M
Nihon Rinsho; 2016 Oct; 74(10):1683-1687. PubMed ID: 30551280
[TBL] [Abstract][Full Text] [Related]
13. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.
White AA; Doherty TA
Am J Rhinol Allergy; 2018 Jan; 32(1):7-11. PubMed ID: 29336282
[TBL] [Abstract][Full Text] [Related]
14. Lipid-mediated innate lymphoid cell recruitment and activation in aspirin-exacerbated respiratory disease.
Cavagnero KJ; Doherty TA
Ann Allergy Asthma Immunol; 2021 Feb; 126(2):135-142. PubMed ID: 32950684
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory heterogeneity in aspirin-exacerbated respiratory disease.
Scott WC; Cahill KN; Milne GL; Li P; Sheng Q; Huang LC; Dennis S; Snyder J; Bauer AM; Chandra RK; Chowdhury NI; Turner JH
J Allergy Clin Immunol; 2021 Apr; 147(4):1318-1328.e5. PubMed ID: 33189729
[TBL] [Abstract][Full Text] [Related]
16. New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease.
Sehanobish E; Asad M; Jerschow E
Curr Opin Allergy Clin Immunol; 2022 Feb; 22(1):42-48. PubMed ID: 34739410
[TBL] [Abstract][Full Text] [Related]
17. Aspirin desensitization in aspirin-exacerbated respiratory disease: New insights into the molecular mechanisms.
Bobolea I; Del Pozo V; Sanz V; Cabañas R; Fiandor A; Alfonso-Carrillo C; Salcedo MÁ; Heredia Revuelto R; Quirce S
Respir Med; 2018 Oct; 143():39-41. PubMed ID: 30261990
[TBL] [Abstract][Full Text] [Related]
18. Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin-exacerbated respiratory disease.
Eastman JJ; Cavagnero KJ; Deconde AS; Kim AS; Karta MR; Broide DH; Zuraw BL; White AA; Christiansen SC; Doherty TA
J Allergy Clin Immunol; 2017 Jul; 140(1):101-108.e3. PubMed ID: 28279492
[TBL] [Abstract][Full Text] [Related]
19. Aspirin activation of eosinophils and mast cells: implications in the pathogenesis of aspirin-exacerbated respiratory disease.
Steinke JW; Negri J; Liu L; Payne SC; Borish L
J Immunol; 2014 Jul; 193(1):41-7. PubMed ID: 24890720
[TBL] [Abstract][Full Text] [Related]
20. Aspirin or other nonsteroidal inflammatory agent exacerbated asthma.
Ledford DK; Wenzel SE; Lockey RF
J Allergy Clin Immunol Pract; 2014; 2(6):653-7. PubMed ID: 25439353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
